Last updated on July 2020

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Clinical Study Identifier: NCT03518086

Find a site near you

Start Over

Mediendo s.r.o.

Praha 8 - Karlin, Czechia
1.81miles
  Connect »

ISCARE Clinical Centre

Praha 7, Czechia
2.81miles
  Connect »

ISCARE Clinical Centre

Praha 9, Czechia
3.37miles
  Connect »

Klinika ResTrial

Praha, Czechia
5.15miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.